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Polymorphic variation in the human serotonin trans-
porter (SERT; 5-HTT) gene resulting in a lifelong
increase in SERT expression is associated with reduced
anxiety and a reduced risk of affective disorder. Evi-
dence also suggests that sex influences the effect of
this polymorphism on affective functioning. Here we
use novel transgenic mice overexpressing human SERT
(hSERT OVR) to investigate the possible influence of
sex on the alterations in SERT protein expression and
cerebral function that occur in response to increased
SERT gene transcription. SERT binding levels were sig-
nificantly increased in the brain of hSERT OVR mice in
a region-dependent manner. The increased SERT bind-
ing in hSERT OVR mice was more pronounced in
female than in male mice. Cerebral metabolism, as
reflected by a quantitative index of local cerebral glu-
cose utilization (iLCMRglu), was significantly decreased
in many brain regions in hSERT OVR female as com-
pared with wild-type female mice, whereas there was
no evidence for a significant effect in any region in
males. The ability of hSERT overexpression to modify
cerebral metabolism was significantly greater in
females than in males. This effect was particularly pro-
nounced in the medial striatum, globus pallidus, soma-
tosensory cortex, mamillary body, and ventrolateral
thalamus. Overall, these findings demonstrate that the
influence of a lifelong increase in SERT gene transcrip-
tion on cerebral function is greater in females than in
males and may relate, in part, to the influence of sex
on genetically driven increases in SERT protein
expression. VC 2009 Wiley-Liss, Inc.
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5-Hydroxytryptamine (5-HT; serotonin) is impli-
cated in the regulation of emotion and in the etiology of
affective disorders. The serotonin transporter (SERT; 5-
HTT) regulates 5-HT availability through reuptake of
the neurotransmitter into the presynaptic terminal. A
number of polymorphisms in the human SERT gene
(SLC6A4; hSERT) have been found to regulate SERT
protein expression and function. One such polymor-
phism, a 44-bp insertion/deletion (the ‘‘long’’ [l] and
‘‘short’’ [s] allele, respectively) in the promoter (5-
HTTLPR) region of the gene results in differential levels
of SERT expression. Cells expressing two copies of the
‘‘l’’ allele show increased SERT mRNA levels and a 2-
fold increase in 5-HT uptake when compared with those
with one or two copies of the ‘‘s’’ allele (Lesch et al.,
1996). Human individuals homozygous for the ‘‘l’’ allele
also display increased SERT mRNA, binding sites, and
5-HT reuptake when compared to ‘‘s’’ allele homozy-
gotes (Hanna et al., 1998; Little et al., 1998; Greenberg
et al., 1999; Heinz et al., 2000). Interestingly, individuals
homozygous for the ‘‘l’’ allele also exhibit decreased
anxiety (Lesch et al., 1996; Greenberg et al., 2000;
Schinka et al., 2004) and are less likely to experience
depression (Furlong et al., 1998; Mann et al., 2000;
Lotrich and Pollock, 2004; Caspi et al., 2003) than those
homozygous for the ‘‘s’’ allele.
Evidence suggests that sex modulates the influence
of this polymorphism on affective functioning, although
there is inconsistency between studies. In females, the
‘‘s’’ allele has been reported to increase the risk of
depressive symptomology (Brummett et al., 2008; Grabe
et al., 2005; Sjoberg et al., 2006), while no such effect
was found in males. In contrast, several studies report
the opposite (Du et al., 2000; Mizuno et al., 2006) or
no (Ball et al., 1997; Gelernter et al., 1998; Greenberg
et al., 2000) sex effect. Data from transgenic animal stud-
ies are more consistent, where genetically determined
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alterations in SERT expression produce a greater effect
in females. For example, in SERT knockout mice
(SERT KO), the resulting alterations in anxiety-like
behavior (Holmes et al., 2003) and serotonin system
functioning (Li et al., 2000; Kim et al., 2005) are more
pronounced in females. However, it could be argued
that the sex effects found in SERT KO mice, where
SERT function is completely abolished, may be more
pronounced than those in response to more subtle, natu-
rally occurring variations in SERT function, such as
those found in humans.
Recently, a novel mouse has been genetically engi-
neered to overexpress hSERT (hSERT OVR), resulting
in an approximate 2-fold increase in SERT protein
expression (Loder et al., 2000; Jennings et al., 2006).
This animal model allows for the investigation of the
possible modulatory influence of sex on the phenotypic
and endophenotypic outcomes of a subtle alteration in
SERT protein expression. In the present study, we
investigate whether sex influences the increase in SERT
protein expression found in the brain of hSERT OVR
mice. Furthermore, we examined constitutive cerebral
metabolism in hSERT OVR mice, as reflected by an
quantitative index of local cerebral glucose utilization
(iLCMRglu, Dawson et al., 2008), and we also deter-
mine whether the modification of cerebral metabolism




All experiments were subject to local ethical review and
were conducted in accordance with the UK Animals (Scien-
tific Procedures) Act (1986) and European Communities
Directive 86/609. A colony of hSERT OVR mice was gener-
ated as previously described (Loder et al., 2000; Jennings
et al., 2003), and all experiments included both male and
female heterozygous transgenic (hSERT OVR) mice and their
wild-type littermates (CBAxC57BL/6J background, aged 2–
4 months). Animals were group housed (5–6 animals per cage)
under strict environmental conditions with a 12-hr light–dark
cycle (lights on 0700) and a room temperature of 218C 6
18C. Food and water were available ad libitum until the night
before the experiment, at which point access to food was re-
stricted overnight (12 hr before experimental manipulation)
for animals involved in the 2-deoxyglucose imaging study to
obviate any possible hyperglycemia during the experimental
procedure. At approximately 3 weeks before the start of the
experiments, and again at 1 week, vaginal smears were taken
and assessed by trained animal technicians, and the mice were
found to be cycling synchronously with an estrus cycle of 4
days. Thus, tissue collection for the paroxetine binding study
and in the determination of iLCMRglu was spread across 4
consecutive days in order to control for the possible influence
of the estrus cycle in females on these parameters. Within
each group (n 5 6), no one day of the estrus cycle was repre-
sented in any more than two mice.
Measurement of SERT Binding Sites
Brains from hSERT OVR mice (male n 5 6, female
n 5 6) and their wild-type littermates (male n 5 6, female
n 5 6) were rapidly dissected out and frozen in isopentane at
2408C and stored at 2808C before sectioning. Coronal sec-
tions (20 lm) were cut in a cryostat (2208C) and thaw-
mounted onto poly-L-lysine-coated slides (VWR, UK). Two
consecutive sections were mounted onto separate slides for the
duplicate determination of total binding, and a third adjacent
section was mounted onto a separate slide for the assessment
of nonspecific binding. Sections were allowed to dry at room
temperature before being stored at 2808C until the day of
the experiment.
On the day of the experiment, tissue sections were
removed from the freezer and allowed to equilibrate to room
temperature for 30 min. Slides were preincubated in 50 mM
Tris-HCl buffer (120 mM NaCl, 5 mM KCl, pH 7.4, 258C)
for 2 3 5 min. For the determination of total binding, sec-
tions were incubated in the same buffer described above but
containing 0.25 nM [3H]paroxetine (Amersham Bioscience,
UK, specific activity 19.1 Ci/mM) for 2 hr (258C). Nonspe-
cific binding was determined by exposing sections to the same
incubation conditions in the presence of 4 lM citalopram
(Sigma-Aldrich, UK). Sections were then washed in 50 mM
Tris-HCl buffer (4 3 30 min) at 48C before being dipped in
ice-cold distilled water and rapidly dried under a stream of
cold air.
Slides were apposed to X-ray film (Kodak, SB-5) for 6
weeks at 2408C along with a set of precalibrated tritium
standards ([3H] microscales, 0.07–33.6 nCi/mg tissue equiva-
lents, Amersham International, UK) and films were developed
in accordance with the manufacturer’s instructions. Autoradio-
graphic images on x-ray film were analyzed by a computer-
based image analysis system (MCID, Imaging Research Inc.).
The tissue-equivalent [3H] concentration of each brain region
of interest (RoI) was calculated from the mean optical density
of six bilateral measurements, and the optical density–[3H] cal-
ibration curve was generated from the coexposed standards.
The concentration of [3H]paroxetine bound to SERT in each
brain region was then calculated by subtracting the value of
nonspecific binding from the mean total binding (determined
from duplicate measurement) with reference to the specific
activity (19.1 Ci/mM) of the radioligand. Throughout these
studies, there was no evidence of a significant difference in
the level of nonspecific binding between either sex or geno-
type in any RoI. This supports the suggestion that differences
found in [3H]paroxetine binding between both sex and geno-
type are due to alterations in the specific binding of this radio-
ligand to SERT.
Measurement of iLCMRglu
Constitutive iLCMRglu was determined in a total of 23
wild-type (male n 5 11, female n 5 12) and 23 hSERT
OVR (male n 5 11, female n 5 12) conscious mice by the
adapted and validated 2-deoxyglucose autoradiographic imag-
ing technique previously developed in this laboratory (Dawson
et al., 2008). Mice were injected intraperitoneally with 5 lCi
of [14C]-2-deoxyglucose in 0.4 ml of saline at a steady rate
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over a 10-sec period before being returned to their home
cage. At exactly 45 min after isotope injection, animals were
decapitated and a terminal blood sample collected by torso
inversion. The brain was rapidly dissected out intact, frozen in
isopentane (2408C), and stored at 2808C until sectioning.
Blood samples were centrifuged to separate the plasma, and
aliquots were removed for the determination of plasma glu-
cose (10 ll) and 14C (20 ll) concentrations by semiautomated
glucose oxidase assay (Beckman Glucose Analyzer) and liquid
scintillation analysis (Packard, Tricarb 2900TL), respectively.
Frozen brains were sectioned (20 lm) in the coronal
plane in a cryostat. A series of three consecutive sections were
retained from every 120 lm, thaw mounted, and rapidly dried
on a hot plate (708C). Autoradiograms were generated by
apposing these sections, together with precalibrated 14C-stand-
ards (40–1,069 nCi/mg tissue equivalents; Amersham Interna-
tional, UK) to X-ray film (Kodak, SB-5) for 7 days. Autora-
diographic images were analyzed by a computer-based image
analysis system (MCID/M51). The local isotope concentra-
tion for each brain RoI was derived from the optical density
(OD) of autoradiographic images relative to that of the coex-
posed 14C standard. Measurements were taken from 46 ana-
tomically distinct brain regions defined with reference to a
stereotactic mouse brain atlas (Franklin and Paxinos, 1997).
iLCMRglu was calculated from the 14C-isotope concentration
in each brain region and the terminal plasma [14C]/[glucose]
ratio in accordance with the operational equation (Fig. 1) for
this methodology. The use of this analytical approach has pre-
viously been shown to provide a valid measure of cerebral
metabolism (Dawson et al., 2008), which parallels measure-
ments gained by using the originally method outlined by
Sokoloff et al. (1977). The experimental procedure applied
here is also less invasive and reduces the stress experienced by
the animals by avoiding the requirement for both intravascular
cannulation and prolonged restraint, which are necessary in
the original methodology.
Statistical Analysis
Data from [3H]paroxetine binding and constitutive 2-
deoxyglucose studies were analyzed by two-way analysis of
variance (ANOVA) with sex (male, female) and genotype
(wild type, hSERT OVR) as dependent variables. Within
both studies, a significant genotype effect was analyzed within
sex by two-way ANOVA with Bonferroni post hoc correc-
tion for multiple comparisons. In iLCMRglu studies, in keep-
ing with previous studies of similar experimental design, ana-
tomically discrete brain regions were assumed to represent
variables that can be analyzed independently within each mea-
sure (McCulloch et al., 1982), and no correction was applied
for multiple comparisons. In addition, the influence of sex on
the ability of hSERT overexpression to alter the global level
of cerebral metabolism was analyzed by the Mann-Whitney
U-test comparison of the difference (ratio) between hSERT
OVR and wild-type mice (within sex). Plasma variables for
the 2-deoxyglucose study were analyzed by Student’s t-test
with Bonferroni post hoc correction applied for multiple
comparisons. Significance was set at P < 0.05 throughout.
RESULTS
SERT Binding Sites in Male and Female
hSERT OVR Mice
The distribution and concentration of [3H]paroxetine
binding in this study was similar to that reported by
others in the brains of rats (DeSouza and Kuyatt, 1987;
Reader et al., 1998; Sharkey et al., 1991). In all animals,
[3H]paroxetine binding was highest in the dorsal and me-
dian raphe´, the molecular layer of the hippocampus,
amygdaloid nuclei, hypothalamus, and the substantia
nigra. Medium levels of binding were evident in subre-
gions of the hippocampus and the nucleus accumbens,
whereas relatively low levels of binding were detected in
the striatum and anterior cortical regions [e.g., medial
prefrontal cortex (mPFC), anterior cingulate, and frontal
cortex].
In the majority of brain regions, [3H]paroxetine
binding tended to be greater in females than in males.
Indeed, [3H]paroxetine binding was found to be signifi-
cantly higher in females compared with males in 19 of
the 42 brain regions analyzed. This effect was particularly
prevalent in cortical regions (including the dorsal mPFC
165%, posterior cingulate 197%, and somatosensory cor-
tex 146%), the hippocampus (including the dentate PO
153%, CA2 130%, ventral CA1 151%), components of
the basal ganglia (medial striatum 127%, globus pallidus
170%) and thalamic regions (mediodorsal 147%, ventro-
lateral 1173%) (Fig. 2, Table I). In contrast, there was no
evidence for a significant sex difference in [3H]paroxetine
binding in any of the amygdaloid or raphe´ nuclei.
In both male and female animals, the density of
[3H]paroxetine binding tended to be greater in hSERT
OVR mice compared with wild-type animals in the ma-
jority of brain areas. In males, [3H]paroxetine binding
was significantly increased in hSERT OVR mice in 5 of
the 42 brain regions analyzed (Fig. 2, Table I). In
Fig. 1. Operational equation for the determination of iLCMRglu.
Ci*(T) represents the total [
14C] present in a single brain region.
Cp*(t) indicates the concentration of [
14C]-2-DG, and Cp(t) indicates
the concentration of glucose present in the terminal blood sample.
(Cp*(t)/Cp(t))individual represents the terminal plasma [
14C]/[glucose]
ratio for an individual animal, mean(Cp*(t)/Cp(t))group represents the
mean plasma ratio of the appropriate experimental (treatment) group
for the given individual animal, and mean(Cp*(t)/Cp(t))control group
represents the mean plasma ratio of the chosen control group.
Adapted from Dawson et al. (2008).
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females, significant increases in [3H]paroxetine binding
in hSERT OVR mice were more widespread, occurring
in 12 brain regions. This suggests that sex may modulate
the ability of hSERT overexpression to increase SERT
protein levels, with a greater effect being observed in
females than in males. Indeed, a significant sex 3 geno-
type interaction was found in the septal nucleus (F1,32 5
4.37, P < 0.05) and dorsal subiculum (F1,34 5 4.85,
P < 0.05), where the ability of hSERT overexpression
to increase [3H]paroxetine binding was significantly
more marked in females than in males.
Interestingly, [3H]paroxetine binding was not sig-
nificantly altered in hSERT OVR animals in a number
of brain regions, including the piriform cortex (18%) or
any of the amygdaloid nuclei (range 25% to 18%),
indicating that increased SERT protein expression in
hSERT OVR mice is regionally heterogenous (Fig. 2,
Table I).
Fig. 2. [3H]Paroxetine binding (fmol/
mg tissue) in eight representative brain
regions of wild-type and hSERT OVR
male and female mice. Data were ana-
lyzed by two-way ANOVA. *P <
0.05 significant genotype effect (within
sex with Bonferroni correction
applied). #P < 0.05 significant sex
effect. 1P < 0.05 significant sex 3 ge-
notype interaction.
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TABLE I. [3H]Paroxetine Binding in hSERT OVR and Wild-type Micey
Site
Male Female
Wild type hSERT OVR
%
Difference
Wild type hSERT OVR
%
DifferenceMean SEM Mean SEM Mean SEM Mean SEM
Cortex
Orbitofrontal 52 6 7 70 6 6* 35 53 6 5 76 6 6* 43
Frontal 72 6 9 87 6 6 21 66 6 6 82 6 6 23
Anterior cingulate 38 6 6 57 6 9 52 50 6 6# 81 6 7#,* 60
Dorsal medial prefrontal 40 6 5 55 6 6 37 69 6 9# 84 6 6# 22
Ventral medial prefrontal 45 6 5 68 6 5* 50 73 6 5# 83 6 8# 13
Somatosensory 56 6 8 70 6 9 24 69 6 7# 118 6 12#,* 71
Temporoparietal 30 6 8 59 6 7* 99 53 6 6 78 6 7 45
Posterior cingulate 18 6 5 34 6 5 94 31 6 6# 75 6 9#,* 140
Piriform 88 6 9 101 6 11 14 84 6 12 86 6 12 2
Entorhinal 87 6 9 88 6 10 2 72 6 4 96 6 8 33
Basal ganglia
Medial striatum 47 6 6 63 6 6 34 55 6 6# 87 6 9#,* 59
Lateral striatum 34 6 7 47 6 9 37 36 6 5# 68 6 6#,* 85
Globus pallidus 35 6 6 58 6 7* 66 74 6 4# 86 6 9# 17
Subthalamic nucleus 42 6 6 45 6 9 7 37 6 5 32 6 5 213
Substantia nigra pars reticulata 88 6 5 102 6 9 16 113 6 11# 120 6 12# 7
Substantia nigra pars compacta 74 6 6 91 6 7 22 90 6 4 113 6 12 25
Amygdala
Medial 86 6 12 82 6 7 25 91 6 13 103 6 9 13
Basolateral 87 6 12 83 6 7 24 99 6 11 92 6 7 27
Central 83 6 11 80 6 7 24 80 6 10 96 6 6 20
Thalamic nuclei
Anterior 56 6 5 61 6 6 11 59 6 8 76 6 7* 28
Mediodorsal 43 6 7 51 6 4 21 56 6 7# 84 6 9#,* 51
Ventrolateral 15 6 5 22 6 5 5 50 6 9# 45 6 5# 210
Hypothalamic nuclei
Anterior 81 6 8 88 6 5 8 93 6 8# 114 6 11# 21
Ventrolateral 69 6 7 84 6 5 21 84 6 9 101 6 16 19
Hippocampal
Molecular layer 103 6 6 101 6 7 22 103 6 13 105 6 7 2
Dorsal subiculum 63 6 4 76 6 9 20 56 6 9 78 6 4*,1 40
Dentate PO 22 6 7 36 6 6 58 38 6 3# 48 6 6# 27
Dorsal CA1 48 6 6 61 6 5 27 61 6 5# 80 6 4#,* 31
CA2 66 6 6 70 6 6 5 85 6 8# 92 6 8# 8
Ventral CA1 63 6 8 67 6 5 6 92 6 8# 104 6 8# 13
Ventral subiculum 79 6 7 89 6 7 13 90 6 9 96 6 8 6
CA3 56 6 6 64 6 7 14 63 6 6# 80 6 6# 27
Raphe´
Dorsal 90 6 9 107 6 11 19 74 6 7 97 6 4 32
Median 60 6 8 84 6 8 40 59 6 4 81 6 7 38
Paramedian 47 6 9 58 6 8 23 53 6 5 56 6 4 6
Mesocorticolimbic system
Ventral tegmental area 30 6 5 53 6 7* 79 53 6 5# 69 6 9#,* 30
Nucleus accumbens 57 6 4 70 6 3 23 71 6 5 73 6 7 3
Multimodal
Septal nucleus 77 6 8 84 6 6 8 68 6 5 101 6 5*,1 48
Bed nucleus of the stria terminalis 55 6 5 71 6 9 28 82 6 6# 94 6 11# 15
Lateral habenula 52 6 8 61 6 6 18 63 6 5 45 6 8 228
Periaqueductal gray 68 6 8 78 6 7 13 76 6 12 93 6 8 22
yEffect of hSERT overexpression on [3H]paroxetine binding (fmol/mg tissue) in the central nervous system. Data are expressed as mean 6 SEM and
percentage change in hSERT OVR mice compared with wild-type animals of the same sex. Data were analyzed by two-way ANOVA.
#P < 0.05 sex difference.
*P < 0.05, significant genotype effect (within sex with Bonferroni correction).
1P < 0.05 significant sex 3 genotype interaction.
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Constitutive iLCMRglu
In all brain regions, iLCMRglu tended to be lower
in females than in males, and this was confirmed by the
significant sex effect observed in 33 of the 46 brain
regions analyzed. The most marked difference between
the sexes was present in the anterior hypothalamus
(mean 40% lower in females). iLCMRglu was signifi-
cantly lower in females compared with males in all hip-
pocampal subregions (minimum effect 214%, maximum
effect 226%) as well as in all amygdala (minimum
223%, maximum 226%) and raphe´ (minimum 221%,
maximum 226%) nuclei.
In males, there was no evidence for a significant
effect of hSERT OVR on iLCMRglu in any RoI. In
contrast, in females, hSERT overexpression produced a
significant reduction in iLCMRglu in 34 of the 47 brain
regions analyzed. In females, significant decreases in
iLCMRglu were found in all cortical regions (range,
231% in piriform cortex to 244% in frontal cortex),
raphe´ nuclei (236/37%), amygdala nuclei (range, 230%
in central to 236% in basolateral), and in multiple hip-
pocampal subfields (range, 234% in dorsal subiculum to
238% in the dorsal CA1) (Table II). This suggested that
the ability of hSERT OVR to modify constitutive
LCMRglu was influenced by sex. Indeed, the effect of
hSERT OVR on the global level of cerebral metabolism
was significantly greater in females than in males (Mann-
Whitney U-test). Furthermore, when looking at each
brain RoI independently a significant sex 3 genotype
interaction was detected in 7 of the 46 brain regions an-
alyzed (Fig. 3). These were detected in the medial stria-
tum (26% greater reduction in females; F1,39 5 4.34,
P < 0.05), globus pallidus (25% greater reduction in
females; F1,38 5 4.39, P < 0.05), ventrolateral thalamus
(32% greater reduction in females; F1,39 5 5.52, P <
0.05), and the mammillary body (27% greater reduction
in females; F1,32 5 5.86, P < 0.05).
The terminal plasma 14C and glucose concentra-
tions for hSERT OVR and wild-type mice involved in
the iLCMRglu study are shown in Table III. There was
no evidence for a significant difference in these plasma
variables between hSERT OVR and wild-type mice in
either sex. Significant sex differences in terminal plasma
glucose and 14C levels, the former of which are at the
lower end of the normal physiological range as a result
of the overnight food restriction implemented in these
studies, most likely results from the lower body weight
of females compared with males. These differences result
in a significant and appropriate sex-based adjustment of
the plasma [14C]:[glucose] ratio for use in the determina-
tion of iLCMRglu and so differences in these plasma
variables are unlikely to contribute to the sex differences
in iLCMRglu found in this study.
DISCUSSION
Given the known influence of sex in affective disor-
ders and reported sex differences in serotonergic system
function (for review, see Rubinow et al., 1998), there is
a paucity of data on sex differences in SERT expression.
However, there is evidence that the density of high-
affinity [3H]imipramine binding sites is greater in the
brain of female rats (Ieni et al., 1985) and that b-CIT
(2-beta-carboxymethoxy-3beta-(4-iodiphenyl)tropane),
which labels both SERT and the dopamine transporter
(DAT), is higher in human females than males (Staley
et al., 2001). This provides some indirect support for our
data showing significantly higher [3H]paroxetine binding
to SERT in a number of diverse brain regions in female
mice when compared with males. Although the sex ste-
roids may have a role in determining observed sex differ-
ences in SERT protein expression, the exact relationship
may not be simple. Thus, although exogenous estrogen
has been found to stimulate both SERT gene transcription
and protein expression levels (McQueen et al., 1997), the
effects are highly localized in the brain, and the pattern
does not match the regional distribution of sex differences
found in naturally cycling mice in our study. Furthermore,
testosterone in males has been found to stimulate SERT
expression (McQueen et al., 1999) almost as much as
estrogen does in females. Therefore, it seems unlikely that
sex differences in SERT expression are determined solely
by the acute regulatory effects of the sex steroids. What-
ever the mechanism, sex differences in SERT protein
expression and function are likely to contribute to some
of the sexual dimorphisms reported in functions associated
with the 5-HT system, including sex differences in affec-
tive function and antidepressant efficacy. In particular, the
enhanced expression of SERT in females may prove to be
central to the decreased levels of synaptic 5-HT found in
females compared with males (Gundlah et al., 1998; Jones
and Lucki, 2005; Mitsushima et al., 2006).
Applying the same radioligand imaging that we
used in wild-type mice, we found that although
[3H]paroxetine binding was increased in hSERT OVR
mice, the regional distribution of binding was qualita-
tively similar to that found in wild-type mice, as
reported previously (Jennings et al., 2006). Furthermore,
the pattern was essentially similar to that described using
a variety of selective SERT radioligands in rats (DeSouza
and Kuyatt, 1987; Reader et al., 1998; Sharkey et al.,
1991). The expression of both murine and human
SERT proteins in hSERT OVR mice results in the
presence of more than one pharmacologically defined
binding site for SERT ligands (Loder et al., 2000), pre-
sumably as a result of the differing affinities of murine
compared with the human transporter for these ligands
(Plenge and Mellerup, 1991). However, the use of a sat-
urating concentration of radioligand in our studies for
both species of SERT proteins allows us to suggest that
it is increased SERT protein expression (Bmax) rather
than altered affinity that accounts for the increased
[3H]paroxetine binding found in hSERT OVR mice.
Interestingly, we also found that the reported enhance-
ment of SERT gene transcription, as reflected by the
increase in SERT mRNA observed in the raphe´ nuclei
of hSERT OVR mice (Jennings et al., 2006), does not
result in a universal increase in SERT protein expression
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TABLE II. Constitutive iLCMRglu in hSERT OVR and Wild-type Micey
Site
Male Female
Wild type hSERT OVR % Wild type Hsert OVR %
Cortex
Orbitofrontal 58 6 6 50 6 5 214 43 6 4# 31 6 3#,* 236
Frontal 43 6 5 36 6 4 216 44 6 3 25 6 2* 244
Anterior cingulate 46 6 5 38 6 4 215 43 6 3 27 6 3* 238
Dorsal medial prefrontal 44 6 6 35 6 3 221 37 6 3# 23 6 2#,* 239
Ventral medial prefrontal 40 6 4 31 6 3 221 29 6 2# 17 6 2#,* 240
Somatosensory 51 6 5 46 6 5 29 55 6 5 28 6 3* 244
Temporoparietal 51 6 5 47 6 5 28 44 6 4# 28 6 2#,* 235
Posterior cingulate 49 6 5 47 6 5 26 48 6 4 32 6 3* 234
Piriform 29 6 3 24 6 2 217 20 6 2# 14 6 2#,* 231
Entorhinal 34 6 3 30 6 3 214 30 6 2# 19 6 2# 235
Basal ganglia
Medial striatum 41 6 3 38 6 4 27 42 6 3 25 6 3*,1 240
Lateral striatum 46 6 4 40 6 4 212 42 6 3# 26 6 3#,* 237
Globus pallidus 30 6 2 28 6 3 29 33 6 3 18 6 2*,1 244
Subthalamic nucleus 46 6 5 45 6 5 22 50 6 4 30 6 3* 234
Substantia nigra pars reticulata 29 6 2 27 6 2 27 26 6 2# 17 6 2#,* 235
Substantia nigra pars compacta 36 6 3 33 6 3 29 34 6 3# 21 6 2#,* 239
Amygdala
Medial 24 6 2 21 6 2 214 18 6 2# 12 6 2# 232
Basolateral 33 6 2 30 6 3 29 29 6 2# 18 6 2#,* 236
Central 22 6 2 19 6 2 212 17 6 2# 12 6 2# 230
Thalamic nuclei
Anterior 47 6 4 47 6 5 0 47 6 5 32 6 3 232
Mediodorsal 54 6 5 47 6 4 214 48 6 4# 29 6 3#,* 239
Ventrolateral 53 6 5 50 6 5 26 56 6 5 31 6 3*,1 246
Hypothalamic nuclei
Anterior 37 6 6 34 6 4 29 19 6 3# 13 6 2# 234
Ventrolateral 28 6 2 27 6 3 23 26 6 2# 16 6 2#,* 237
Hippocampus
Molecular layer 41 6 4 34 6 3 216 32 6 3# 21 6 2#,* 235
Dorsal subiculum 38 6 3 34 6 3 211 38 6 3 25 6 3* 234
Dentate PO 25 6 1 22 6 2 211 20 6 2# 15 6 2# 225
Dorsal CA1 35 6 3 30 6 2 216 28 6 3# 17 6 2#,* 238
CA2 33 6 3 27 6 3 218 26 6 3# 16 6 2#,* 238
Ventral CA1 33 6 2 28 6 3 216 24 6 2# 17 6 2# 231
Ventral subiculum 29 6 2 26 6 3 211 23 6 2# 17 6 2# 226
CA3 27 6 2 24 6 2 214 21 6 2# 14 6 2# 234
Raphe´
Dorsal 36 6 3 31 6 3 214 29 6 2# 18 6 2#,* 237
Median 46 6 5 39 6 4 215 39 6 3# 25 6 3#,* 236
Paramedian 45 6 4 39 6 4 213 40 6 3# 25 6 3#,* 237
Mesocorticolimbic system
Ventral tegmental area 36 6 3 37 6 5 2 43 6 4 28 6 3* 235
Nucleus accumbens 43 6 6 34 6 3 221 31 6 2# 19 6 2#,* 240
Multimodal
Septal nucleus 34 6 3 29 6 3 213 29 6 2# 18 6 2#,* 237
BNST 27 6 3 21 6 2 221 17 6 2# 11 6 2# 235
Lateral habenula 53 6 5 48 6 5 210 55 6 4 32 6 3* 241
Mamillary body 52 6 4 50 6 5 23 56 6 3 34 6 3*,1 239
Periaqueductal grey 33 6 3 26 6 2 220 23 6 3# 15 6 2# 234
Inferior colliculus 73 6 7 71 6 10 23 81 6 7 48 6 5 240y
Ventral tegmental nucleus 46 6 4 41 6 4 212 43 6 3# 26 6 2#,* 240
Locus coeruleus 41 6 4 36 6 4 213 38 6 3# 22 6 2#,* 242
Nucleus tractus solitaris 56 6 9 44 6 7 220 37 6 4# 17 6 1# 252
yConstitutive iLCMRglu (nCimg21/nCilmol21) in male and female hSERT OVR and wild-type mice. Data shown as mean 6 SEM iLCMRglu
and % change in hSERT OVR mice compared with wild-type animals of the same sex. Data were analyzed by two-way ANOVA.
#P < 0.05 significant sex effect.
*P < 0.05 significant hSERT effect within sex (two-way ANOVA with Bonferroni correction).
1P < 0.05 significant sex 3 genotype interaction.
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throughout the brain. Rather, SERT expression is
enhanced in a regionally heterogenous manner, with the
greatest increase found in anterior cortical regions, mod-
erate increases in components of the basal ganglia, hip-
pocampal regions, and raphe´, while in other regions,
such as the amygdala nuclei, no increase is observed.
This suggests that the increased SERT protein expression
in hSERT OVR mice is not directly related to the
enhancement of SERT gene transcription. Rather, com-
plicated regulatory mechanisms must exist that govern
SERT protein expression levels, and these must operate
in a brain region–specific manner. As yet, the nature of
these mechanisms is not understood, but because they
will directly regulate the outcome of enhanced SERT
gene transcription, they are likely to be central in media-
ting altered serotonergic function in hSERT OVR mice.
The same mechanisms may also mediate the effects of
the 5-HTTLPR polymorphism on brain and affective
functioning in humans.
The approximate 2-fold increase in SERT binding,
in specific brain regions of hSERT OVR mice, shows a
striking parallel to the magnitude of increase (also
approximately 2-fold) in SERT binding, mRNA expres-
sion, and 5-HT reuptake found in both brain and blood
platelets of human individuals with the l/l genotype over
those of the s/l or s/s genotype (Greenberg et al., 1999;
Heinz et al., 2000; Little et al., 1998). This adds further
credence to the suggestion that hSERT OVR mice pro-
vide a useful model of the natural variation in SERT
protein expression observed in humans—for example, as
a result of the 5-HTTLPR polymorphism. However, it
is also important to note that a number of other studies
have reported that there is no effect of the 5-HTTLPR
polymorphism on SERT binding in the human brain
(Parsey et al., 2006; Shioe et al., 2003; Van Dyck et al.,
2004; Willeit et al., 2001). Although it is interesting to
speculate, with reference to our results, that the regional
localization of the binding measurements made in some
of these studies may be responsible for their negative
findings, it is also likely that the use of small sample sizes
in some of these studies might contribute to their nega-
tive results. More importantly, because our results sug-
gest that the ability of a genetically determined increase
in SERT transcription increases SERT protein expres-
sion is strongly influenced by sex, with greater increases
occurring in females than in males, lack of sample segre-
Fig. 3. Effect of hSERT OVR on constitutive iLCMRglu in male and female mice. Data shown
as percentage difference in the iLCMRglu from appropriate wild-type control. Representative
regions are shown for the (A) maximum and (B) minimum sex difference in the effect of hSERT
overexpression on iLCMRglu. *P < 0.05 significant hSERT effect (within-sex Bonferroni correc-
tion). 1P < 0.05 significant sex 3 hSERT OVR interaction (two-way ANOVA).
TABLE III. Plasma Glucose and 14C in hSERT OVR and Wild-type Micey
Variable
Male Female
Wild type hSERT OVR Wild type hSERT OVR
Plasma glucose (lmolml21) 9.03 6 0.61 7.28 6 0.80 6.52 6 0.44* 7.68 6 0.49
Plasma [14C] (nCiml21) 77.47 6 4.53 75.69 6 8.55 96.05 6 13.57* 138.48 6 18.12*
Plasma [14C]:[glucose] (nCilmol21) 8.41 6 0.65 11.89 6 1.95 15.34 6 2.11* 18.02 6 2.41*
yTerminal plasma 14C (nCiml21) and glucose (lmolml21) concentrations in wild-type and hSERT OVR mice. Data are mean 6 SEM.
*P < 0.05 significant sex difference (within genotype; Student’s t-test with Bonferroni correction).
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gation on the basis of sex in human studies investigating
the 5-HTTLPR polymorphism may be a major con-
founding factor resulting in their negative results.
In this study, we found that a lifelong increase in
SERT function decreases constitutive cerebral metabo-
lism in a number of brain regions, and that this effect
was only significant in females. Interestingly, many of
the regions in which a decreased rate of iLCMRglu was
found in hSERT OVR females compared with wild-
type animals are strongly implicated in the regulation of
anxiety. Pharmacological challenges associated with an
anxiolytic effect, including acute diazepam and pheno-
barbital treatment, commonly result in decreased
LCMRglu in many of the regions in which constitutive
iLCMRglu is decreased in hSERT OVR mice. These
regions include the mamillary body, ventrolateral thala-
mus, septal nucleus, medial striatum, and globus pallidus
(Ableitner et al., 1985; Ableitner and Herz, 1987; Kelly
et al., 1986). In addition, a number of anxiogenic phar-
macological challenges have been reported to elicit
increased LCMRglu in these structures (Pratt et al.,
1988; Ableitner and Herz, 1987) and chronic prenatal
treatment with diazepam, which produces an anxiolytic-
like phenotype in the ‘‘drug-free’’ adult, is also associ-
ated with reduced LCMRglu in many of these brain
regions (Schroeder et al., 1997).
Our data suggest that constitutive cerebral function
is decreased in several brain structures in which neuronal
activity is positively correlated with anxiety. In addition,
elevated LCMRglu in the lateral habenula appears to be
the most robust correlate of depressive behavior in rats,
and this hypermetabolism is reversed, in parallel with the
alleviation of depressive-like behavior, by antidepressant
treatment (Caldecott-Hazard et al., 1988). In this con-
text, it is worth noting that iLCMRglu is also signifi-
cantly decreased in the lateral habenula of hSERT OVR
mice, suggesting that hypometabolism in this region may
contribute to their depression-resistant phenotype. In a
wider context, the observation of decreased constitutive
metabolism in limbic structures of female hSERT OVR
mice parallels the reported basal frontolimbic hypome-
tabolism reported in l/l compared with s/s allele human
individuals (Graff-Guerrero et al., 2005). However, in
contrast to the observation that hypometabolism is lim-
ited to frontal cortical structures in l/l human individu-
als, we found evidence for a more widespread effect in
hSERT OVR female mice, which also included many
subcortical regions and the raphe´ nuclei. One reason for
this disparity may be the lack of sample segregation on
the basis of sex in the human study, which could lead
to the masking of a more widespread hypometabolism in
l/l allele females by the presence of a smaller effect in
males.
Evidence from both [3H]paroxetine binding and
constitutive iLCMRglu data suggests that sex modulates
the influence of a lifelong increase in SERT transcrip-
tion on these parameters, with a greater effect in females
than in males. The greater increase in [3H]paroxetine
binding induced by hSERT overexpression in females
compared with males suggests that direct sex modulation
of the increase in SERT protein expression elicited in
response to increased SERT gene transcription may be
central to the sex-dependent effects of the 5-HTTLPR
polymorphism on affective functioning. However, in
hSERT OVR mice the modulatory influence of sex on
increased SERT expression was limited in its regional
distribution, being significant in the dorsal subiculum
and septal nucleus. In contrast, the influence of sex on
the cerebral hypometabolism present in hSERT OVR
animals was more widespread and did not include either
the dorsal subiculum or septum. Furthermore, the
regions in which iLCMRglu was altered by hSERT
OVR to a greater extent in females than in males do
not receive dense innervation from either the dorsal sub-
iculum or septum. Thus, in terms of anatomical distribu-
tion, the effect of sex on the ability of hSERT overex-
pression to induce cerebral hypometabolism does not
directly map onto the effect of sex on the altered SERT
expression levels in these animals. However, it is com-
monly reported that regional alterations in LCMRglu in
response to pharmacological challenge do not correlate
with the regional distribution of receptors. This is
thought to be due to both the sensitivity of the method,
which localizes metabolic alterations at the synapse rather
than cell body and to the convergence and contribution
of polysynaptic pathways to the observed alterations in
LCMRglu. Therefore, it is not surprising that the sex
effects of hSERT OVR on SERT protein expression
show little spatial correlation with those of iLCMRglu.
Furthermore, sex-dependent modulation of any altera-
tion in 5-HT receptor functioning that may occur in
response to the altered SERT function present in
hSERT OVR animals may also contribute to the differ-
ences noted in iLCMRglu. Such a mechanism has been
found to exist in SERT KO mice where alteration in 5-
HT1A receptor function are found in female, but not
male, animals (Li et al., 2000).
Overall, these data suggest that a lifelong increase
in SERT transcription modifies constitutive cerebral
function to a greater extent in females than in males.
Although this finding parallels reported sex differences
observed in humans in the effect of the 5-HTTLPR
polymorphism on affective functioning, the possible sex
difference in anxiety-like behavior in hSERT OVR ani-
mals has not been investigated. However, our data sug-
gest that hSERT overexpression may produce a greater
anxiolytic effect in females than in males. In summary,
alterations in SERT expression and cerebral function in
hSERT OVR mice parallel those observed in l/l allele
human individuals, suggesting that hSERT OVR mice
provide a useful animal model of the 5-HTTLPR poly-
morphism. In addition, these alterations are greater in
females than in males, which parallels the known sex dif-
ference in the effect of the 5-HTTLPR polymorphism
on affective functioning in humans.
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